+

WO2008116044A8 - Points quantiques de semi-conducteurs pour l'administration et la prise d'image intracellulaire efficaces des arnsi - Google Patents

Points quantiques de semi-conducteurs pour l'administration et la prise d'image intracellulaire efficaces des arnsi

Info

Publication number
WO2008116044A8
WO2008116044A8 PCT/US2008/057611 US2008057611W WO2008116044A8 WO 2008116044 A8 WO2008116044 A8 WO 2008116044A8 US 2008057611 W US2008057611 W US 2008057611W WO 2008116044 A8 WO2008116044 A8 WO 2008116044A8
Authority
WO
WIPO (PCT)
Prior art keywords
efeicient
sirna
delivery
quantum dots
semiconductor quantum
Prior art date
Application number
PCT/US2008/057611
Other languages
English (en)
Other versions
WO2008116044A1 (fr
Inventor
Shuming Nie
Xiaohu Gao
Maksym Yezhelyev
Original Assignee
Univ Emory
Shuming Nie
Xiaohu Gao
Maksym Yezhelyev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Shuming Nie, Xiaohu Gao, Maksym Yezhelyev filed Critical Univ Emory
Publication of WO2008116044A1 publication Critical patent/WO2008116044A1/fr
Publication of WO2008116044A8 publication Critical patent/WO2008116044A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Ceramic Engineering (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention se rapporte à des nanostructures, des procédés de préparation de nanostructures, des procédés de détection de cibles chez des sujets, et des procédés de traitement des maladies chez des sujets. Un mode de réalisation, entre autres, des nanostructures comprend un point quantique et une structure de protection hydrophobe. Ladite structure de protection hydrophobe comprend un ligand de coiffage et un copolymère amphiphile, ladite structure de protection hydrophobe encapsulant le point quantique.
PCT/US2008/057611 2007-03-20 2008-03-20 Points quantiques de semi-conducteurs pour l'administration et la prise d'image intracellulaire efficaces des arnsi WO2008116044A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91897907P 2007-03-20 2007-03-20
US60/918,979 2007-03-20

Publications (2)

Publication Number Publication Date
WO2008116044A1 WO2008116044A1 (fr) 2008-09-25
WO2008116044A8 true WO2008116044A8 (fr) 2008-12-24

Family

ID=39766446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/057611 WO2008116044A1 (fr) 2007-03-20 2008-03-20 Points quantiques de semi-conducteurs pour l'administration et la prise d'image intracellulaire efficaces des arnsi

Country Status (1)

Country Link
WO (1) WO2008116044A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103897702A (zh) * 2014-04-20 2014-07-02 吉林师范大学 一种ZnSe量子点及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102144279A (zh) 2008-09-03 2011-08-03 爱默蕾大学 量子点、制造量子点的方法以及使用量子点的方法
CN102288765B (zh) * 2011-07-07 2013-12-04 清华大学深圳研究生院 一种基于量子点的免疫荧光检测氯霉素的方法及专用试剂盒
EP4189473A4 (fr) * 2020-08-03 2024-08-28 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Points quantiques protégés pour utilisations thérapeutiques, diagnostiques et autres
CN112370435B (zh) * 2020-11-19 2022-03-29 临沂大学 一种靶向核壳结构载药纳米颗粒及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846412B2 (en) * 2003-12-22 2010-12-07 Emory University Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103897702A (zh) * 2014-04-20 2014-07-02 吉林师范大学 一种ZnSe量子点及其制备方法

Also Published As

Publication number Publication date
WO2008116044A1 (fr) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2005065081A3 (fr) Structures bioconjuguees, procedes de fabrication associes et procedes d'utilisation associes
WO2011057295A3 (fr) Points de polymère chromophore fonctionnalisé et leurs bioconjugués
WO2010005816A3 (fr) Classification d’état postural pour dispositif médical
WO2008116044A8 (fr) Points quantiques de semi-conducteurs pour l'administration et la prise d'image intracellulaire efficaces des arnsi
CA2795096C (fr) Dispositif et procede pour administrer un medicament par voie intra-oculaire
WO2008054523A3 (fr) Nanostructures, procédés de synthèse de celles-ci et procédés d'utilisation de celles-ci
WO2005072709A3 (fr) Preparations pour medicaments peu solubles
MY158687A (en) Micro-needle device and preparation method
WO2006073950A3 (fr) Nanoparticules pour administration de medicament proteine
WO2010036918A3 (fr) Récepteur intracellulaire d'adn
WO2010041015A3 (fr) Émulsions gélifiées pouvant être mâchées
WO2012038061A3 (fr) Nanocapsules contenant des microémulsions
WO2009138473A3 (fr) Libération intracellulaire d'anticorps
EP3988089A4 (fr) Nanoparticules lipidiques pour administration in vivo de médicament, et utilisations associées
WO2009120247A3 (fr) Compositions de nanoparticules de lipides et procédés de préparation et d’utilisation de celles-ci
WO2009098404A8 (fr) Procédé de préparation de nanoparticules à base de molécules ou macromolécules amphiphiles fonctionnelles et leur utilisation
EP2481402A3 (fr) Nanoparticule comportant du rapamycine et albumine en tant qu'agent anti-cancer
WO2010083337A3 (fr) Nanostructures composites et procédés de fabrication et d'utilisation associés
WO2009097480A3 (fr) Libération de médicament déclenchée par un laser pulsé à infrarouge proche à partir de vésicules et vésosomes rompus à nanoenveloppe creuse
MX2015012060A (es) Forma de dosificacion solida de disuasivo del abuso para liberacion inmediata con marca funcional.
WO2011139479A3 (fr) Application à cisaillement élevé utilisée pour l'administration de médicament
WO2009053885A3 (fr) Procédés de préparation de microparticules de polymère
AP2010005389A0 (en) Nanoparticle carriers for drug administration and process for producing same.
WO2009085016A8 (fr) Nanostructures, procédés de préparation et utilisations de celles-ci
WO2009134079A3 (fr) Formulation pharmaceutique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08732541

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08732541

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载